The Technical Analyst
TransCode Therapeutics, [RNAZ]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
TransCode Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.64% $0.502
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.30 mill |
| EPS: | -4 144.40 |
| P/E: | 0 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 6.57 mill |
| Avg Daily Volume: | 0.655 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.419 - 0.585 ( +/- 16.53%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-28 | Fitzgerald Thomas A | Buy | 49 350 | Common Stock |
| 2023-09-28 | Dudley Robert Michael | Buy | 98 000 | Common Stock |
| 2023-06-21 | Dudley Robert Michael | Buy | 12 000 | Common Stock |
| 2023-06-20 | Dudley Robert Michael | Buy | 6 607 | Common Stock |
| 2023-06-09 | Dudley Robert Michael | Buy | 19 000 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 36 transactions |
| Buy: 2 048 457 | Sell: 1 170 653 |
Forecast:
16:00 - $0.482
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.482
Forecast 2: 16:00 - $0.482
Forecast 3: 16:00 - $0.482
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.502 (-4.64% ) |
| Volume | 0.270 mill |
| Avg. Vol. | 0.655 mill |
| % of Avg. Vol | 41.18 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RNAZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Latest Press Releases
2024-04-15 09:00:00 - Press Release
Transcode Therapeutics Announces Fda Clearance To Initiate Phase 1/2 Clinical Trial With Ttx-mc138 In Patients With Advanced Solid Tumors
Boston, april 15, 2024 (globe newswire) -- transcode therapeutics, inc. (nasdaq: rnaz), the rna oncology company committed to more effectively treating cancer using rna therapeutics, announced today that the u.s. food and drug administration (fda) has completed its review of the company's investigational new drug (ind) application and concluded that the company may proceed with its phase 1/2 multicenter, open-label, dose-escalation and dose-expansion study of its lead therapeutic candidate, ttx-mc138, in patients with advanced solid tumors. “we are thrilled to have obtained fda authorization to advance ttx-mc138 into the clinic.
2024-04-03 09:10:00 - Press Release
Transcode Therapeutics Reports 2023 Results; Provides Business Update
Boston, april 03, 2024 (globe newswire) -- transcode therapeutics, inc. (nasdaq: rnaz), the rna oncology company committed to more effectively treating cancer using rna therapeutics, today reported financial results for 2023 and recent business progress. “we believe 2023 was extremely productive and pivotal for transcode.
2024-03-28 08:30:00 - Press Release
Transcode Therapeutics Announces Appointment Of Daniel Vlock, M.d., As Chief Medical Officer
Boston, march 28, 2024 (globe newswire) -- transcode therapeutics, inc. (nasdaq: rnaz), the rna oncology company committed to more effectively treating cancer using rna therapeutics, announced today that daniel vlock, m.d., has been appointed as the company's chief medical officer.
2024-03-11 09:00:00 - Press Release
Transcode Therapeutics And Akribion Genomics Report Progress Developing Crispr-derived Technology For Cancer Treatment
Boston, march 11, 2024 (globe newswire) -- transcode therapeutics, inc. (nasdaq: rnaz), the rna oncology company committed to more effectively treating cancer using rna therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with akribion genomics. akribion genomics, a german-based biotechnology start-up, is focused on a crispr-derived molecular complex for cancer treatment.
2024-03-06 16:15:00 - Press Release
Transcode Therapeutics To Present At 2024 Rna Leaders Europe Congress
Boston, march 06, 2024 (globe newswire) -- transcode therapeutics, inc. (nasdaq: rnaz), the rna oncology company committed to more effectively treating cancer using rna therapeutics, today announced that its chief scientific officer, zdravka medarova, ph.d., will present at this year's rna leaders europe congress scheduled to take place march 12-14 in basel, switzerland.
Latest News
2024-03-06 16:15:00 - GlobeNewsWire
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year's RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.
2024-01-19 14:11:06 - Zacks Investment Research
TransCode (RNAZ) Down 50% on Issue of New Common Stock
TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
2023-10-27 08:16:45 - InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Friday after the oncology company announced plans for a public share offering. TransCode Therapeutics hasn't yet revealed details of the proposed public stock offering.
2023-09-26 08:48:04 - InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is falling hard on Tuesday after the medical company announced a public share offering. According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each.
2023-09-26 06:47:52 - Proactive Investors
Transcode Therapeutic stock whipsaws lower after cut price placing
TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-hours equity raise. On the back of preclinical results the RNA oncology stock traded as high as $3.20 and closed at $2.55, from a starting price of 66 cents.
2023-09-25 13:14:40 - InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Up 240% Today?
Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ: RNAZ ) saw its shares drive up 300% earlier this morning before settling around 240% up in the early afternoon session. Catapulting sentiment was news that TransCode's lead therapeutic candidate, TTX-MC138, demonstrated encouraging pre-clinical results.
2023-09-25 10:38:22 - Proactive Investors
TransCode Therapeutics stock skyrockets on positive brain cancer trial results
TransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice models bearing human glioblastoma multiforme (GBM) tumors. Shares of the Boston-based RNA oncology company added 30.8.1% to US$2.71 in early trade on Monday.
2023-07-10 11:00:12 - Zacks Investment Research
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
TransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2023-04-06 07:00:00 - GlobeNewsWire
TransCode Therapeutics to present at AACR Annual Meeting 2023
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will present new results and a clinical study overview at the Phase I and First-in-Human Clinical Trials in Progress Session at the 2023 American Association of Cancer Research (AACR) Annual Meeting to be held April 14-19. Studies to be highlighted as part of the Meeting's Poster Sessions include:
2023-03-03 14:22:29 - PennyStocks
10 Penny Stocks Under $1 To Watch Now, Time To Buy?
Penny stocks under $1 The post 10 Penny Stocks Under $1 To Watch Now, Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.